Ji et al. found that miR-486-3p was significantly downregulated in sorafenib-resistant HCC cell lines, further validating FGFR4 and EGFR as targets of miR-486-3p, and overexpression of miR-486-3p in combination with sorafenib could significantly inhibit tumor growth in a sorafenib resistance model (Ji et al., 2020). The gene discussed is EGFR; the disease is neoplasm.